АИВ-ИНФЕКЦИЯЛАНҒАН НАУҚАСТАРДАҒЫ СОЗЫЛМАЛЫ С ГЕПАТИТІНІҢ ЕМДЕУ ЕРЕКШЕЛІКТЕРІ: ӘДЕБИЕТТЕРДІ ШОЛУ
АИВ-инфекциясымен астасқан иммун жетіспеушіліктің жағдайы вирустық гепатиттің ағымын тездетуге жәрдемдеседі. Қазіргі уақытта АИВ-инфекцияланған науқастар арасынан С вирусті гепатитті тудырған індет кеңінен тарап отыр. Мақалада АИВ-инфекцияланған науқастардағы созылмалы C гепатитінің емдеу ерекшеліктері туралы әдебиеттің тізімі берілген.
Н. Е. Сәрсекеева, Б. Н. Кошерова
Қарағанды мемлекеттік медицина университеті, Караганда қ., Қазақстан
Литература:
1. Бакулин И. Г., Киселева А. В. Практические аспекты применения трехкомпонентной терапии при хроническом гепатите С // Терапевтический архив. 2013. № 11. С. 91-100.
2. Бацких С. Н., Морозов С. В., Чуланов В. П., Покровский В. И. Вирус гепатита С 3-го генотипа: такой «простой», такой «сложный» // Терапевтический архив. 2012. № 11. С. 4.
3. Буеверов А. О. Профилактика и коррекция гематологических побочных эффек-тов противовирусной терапии хронического гепатита С // Рос. журн. гастроэнтерол., гепатол., колопроктол. 2009. № 3. С. 76-82.
4. ВИЧ-инфекция и СПИД: национальное руководство / Под ред. В. В. Покровского. М.: ГЭОТАР-Медиа, 2013. 608 с.
5. Громова И. И., Богомолов Б. П. Сравнительная эффективность и побочные реакции при комбинированной противо-вирусной терапии больных хроническим гепатитом С // Клиническая медицина. 2008. № 9. С. 43-46.
6. Доскожаева С. Т., Петрова Н. П. Терапия хронического вирусного гепатита С у больных ВИЧ-инфекцией // Медицина. 2008. № 8. С. 10-13.
7. Ивашкин В. Т., Маевская М. В., Морозова М. А., Люсина Е. О. Современные схемы лечения больных хроническим гепатитом С // Рос. журн. гастроэнтерол., гепатол., колопроктол. 2012. № 1. С. 36-45.
8. Инфекционные болезни: национальное руководство / Под ред. Н. Д. Ющука, Ю. Я. Венгерова. M.: GEOTAR-Media, 2009. 1056 c.
9. Касымова Т. В. Побочные действия противовирусного лечения хронического вирусного гепатита С // Вестник ЮКГФА. 2012. № 3. С. 128-130.
10. Максимов С. Л., Иванова Л. М., Кравченко А. В., Серебровская Л. В., Ольшанский А. Я., Моргунова Н. М., Ющук Н. Д. Особенности терапии хронического гепатита С пегилированным интерфероном α2а и рибавирином у больных ВИЧ-инфекцией // Терапевтический архив. 2007. № 11. С. 40.
11. Минаева С. В., Мошкович Г. Ф., Горяева М. П., Воронина И. Д. Сравнительные результаты лечения хронического гепатита С у больных ВИЧ-инфекцией, получающих и не получающих антиретровирусную терапию // Эпидемиология и инфекционные болезни. 2010. № 3. С. 35-38.
12. Резолюция первой Европейской согласительной конференции по лечению хронических гепатитов В и С у ВИЧ-инфицированных. Стандарты медицины. 2006. № 1. С. 39-48.
13. Саркисянц Н. К., Григорян Э. Г. Опыт прогнозирования побочных эффектов лечения хронического гепатита С пегинтерфероном α-2А с рибавирином // Клиническая медицина. 2013. № 5. С. 46-49.
14. Скляр Л. Ф., Горелова И. С., Ли Ю. А. Противовирусная терапия парентеральных гепатитов у ВИЧ-инфицированных пациентов в Приморском крае // Тихоокеанский медицинский журнал. 2009. № 4. С. 80-82.
15. Федорченко С. В., Мартынович Т. Л., Ляшко О. В., Карюк Ж. А., Янченко В. И. Спонтанный клиренс HCV: связь с полом, возрастом, генотипом вируса, путями передачи инфекции, маркерами HBV и HIV // Терапевтический архив. 2010. № 3. С. 52.
16. Шахгильдян В. И. Современные подходы к лечению HCV-инфекции у ВИЧ-инфицированных. Гепатол. форум. 2008. № 4. С.16-27.
17. Ющук Н. Д., Максимов С. Л., Иванова Л. М., Климова Е. А., Знойко О. О., Кравченко А. В. Комбинированная терапия хронического гепатита С пегилированным интерфероном α-2а и рибавирином у больных с ВИЧ-инфекцией и больных с моноинфекцией HCV // Рос. журн. гастроэнтерол., гепатол., колопроктол. 2009. № 1. С. 35-43.
18. Andreoni M. et al. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications // Eur Rev Med Pharmacol Sci. 2012. N 16(11). P. 1473-1483.
19. Ascione A. et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomized trial // 43-rd Annual meeting of the European association for the study of the liver (EASL). Apr. 23-27, 2008; Milan, Italy; 2008.
20. Balagopal A. et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C // Gastroenterology. 2008. N 135. P. 226-233.
21. Barreiro P. et al. Comparison of hepatitis C virus early kinetics in HIV/HCV-co-infected patients treated with weight-based ribavirin + either pegIFN alpha-2a or pegIFN alpha-2b // 14th Conference on retroviruses and opportunistic infections (CROI). Los Angeles, Febr. 25-28, 2007. Abstract 901.
22. Berenguer J. et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus // J Hepatol. 2013. N 58(6). P. 1104-1112.
23. Bichoupan K. et al. Pegylated-IFN α2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new // Expert Opin Biol Ther. 2014. N 14(9). P. 1369-1378.
24. Chapplain J. et al. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial // J Infect. 2013. N 67(4). P. 313-321.
25. Garbuglia A. et al. HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes // Infect Dis. 2014. N 14. P. 222.
26. Gonzales-Garcia J. et al. The use of TDF + 3TC/FTC is associated with an improved response to pegylated interferon + ribavirin in HIV/HCV-co-infected patients receiving HAART: The Gesida 50/06 Study Group // 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, MA. Feb. 3-6, 2008. Abstract 1076.
27. Hepatitis C and HIV-infection: management algorithm in patients with combined infection. WHO Clinical protocol for European region. 2009. URL: http://www.euro.who.int/_data/assets/pdf_file/0010/78148/HEP_C_rus.pdf (дата обращения 03.11.2014).
28. Jain M. et al. Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients // J Viral Hepat. 2015. N 22(1). P. 25-36.
29. Khaykin P. et al. Impact of different ART regimens on efficacy and safety of standard HCV treatment in HIV/HCV co-infected patients // 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract MOREB056.
30. Krämer B. et al. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C // AIDS. 2013. N 27(17). P. 2817-2819.
31. Labarga P. et al. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy // J Viral Hepat. 2014. N 21(7). P. 475-479.
32. Limketkai B. et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV // JAMA. 2012. N 308. P. 370-378.
33. Lu L. et al. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants // J Med Virol. 2005. N 75. P. 538-549.
34. Maida I. et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes // AIDS. 2006. N 22. P. 139-143.
35. Mallolas J. et al. Peginterferon Alfa-2b plus ribavirin for treatment naïve patients coinfected with HCV and HIV // Expert. Rev. Antiinfect. Ther. 2008. N 6. P. 281-289.
36. Mandorfer M. et al. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin // Liver Int. 2014. N 34(1). P. 69-77.
37. Marks K. et al. Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239 // J Acquir Immune Defic Syndr. 2014. N 65(3). P. 345-349.
38. Mira J. et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis // Clin Infect Dis. 2013. N 56(11). P. 1646-1653.
39. Mira J. et al. Efficacy of pegylated interferon + ribavirin treatment in HIV/HCV-co-infected patients receiving abacavir + lamivudine or tenofovir + either lamivudine or emtricitabine as nucleoside analogue backbone // 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, MA. Feb. 3-6, 2008. Abstract 1074.
40. Murphy D. et al. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′untranslated region sequences // Journal of Clinical Microbiology. 2007. N 45. P. 1102-1112.
41. Nunez M. et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial // AIDS Res. Hum. Retroviruses. 2007. N 23. P. 972-982.
42. Nunez M. et al. Extended treatment does not reduce relapses in HIV/HCV-co-infected patients treated with pegylated interferon + weight-dosing ribavirin. In: 14th Conference on retroviruses and opportunistic infections (CROI). Los. Angeles, Febr. 25-28, 2007. Abstract 899.
43. Odolini S. et al. Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV // Infect Dis. 2014. N 14(5).
44. Osinusi A. et al. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients // J Med Virol. 2014. 86(2). P. 177-185.
45. Rivero-Juárez A. et al. Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients // PLoS One. 2012. N 7(11).
46. Rivero-Juarez A. et al. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype // AIDS. 2013. 27(12). P. 1941-1947.
47. Rivero-Juarez A. et al. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy // J Infect. 2014. N 68(4). P. 372-377.
48. Rockstroh J. et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults // HIV Med. 2008. N 9. P. 82-88.
49. Salmon-Ceron D. et al. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1 // Liver Int. 2014. N 34(6). P. 869-889.
50. Sede M. et al. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin // Arch Virol. 2013. 158(9). P. 1907-1915.
51. Serrano-Villar S. et al. Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections // Clin Infect Dis. 2013. N 57(3). P. 458-464.
52. Simmonds P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes // Hepatology. 2005. N 42. P. 962-973.
53. Slim J. et al. The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV // J Int Assoc Provid AIDS Care. 2013. N 12(5). P. 354-362.
54. Sogni P. et al. Management of cirrhosis complications in HIV patients coinfected with hepatitis В or С virus // La Presse Medicaid. 2005. N 20(34). P. 1579-1583.
55. Soriano V. et al. Management of chronic hepatitis B and C in HIV-coinfected patients // J. Antimicrob. Chemother. 2006. N 57. P. 815-818.
56. Soriano V. et al. (PRESCO Study Group). Causes of premature discontinuation in HIV/HCV co-infected patients in PRESCO, a large trial of treatment with pegylated interferon plus weight-based ribavirin. In: 14th Conference on retroviruses and opportunistic infections (CROI). Los. Angeles, Febr. 25-28, 2007. Abstract 905.
57. Soriano V. et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel // AIDS. 2007. N 21. P. 1073-1089.
58. Strazzulla A. et al. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals // Infect Dis. 2014. N 14(5).
59. Sulkowski M. HCV therapy in HIV-infected patients // Liver Int. 2013. 33(1). P. 63-67.
60. Sulkowski M. Management of acute and chronic HCV infection in persons with HIV coinfection // Hepatology. 2014. N 61. P. 108-119.
61. Sulkowski M. Viral hepatitis and HIV coinfection // Hepatology. 2008. N 48. P. 353-367.
62. Tian D. et al. Different HCV genotype distributions of HIV-infected individuals in Henan and Guangxi, China. PLoS One. 2012. N 7(11).
63. Torti C. et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort // AIDS. 2006. N 41. P. 180-185.
64. Vachon M. L. et al. HCV treatment challenges in patients co-infected with HIV // Future HIV Ther. 2009. N 1. P. 87-100.
65. Wandeler G. et al. Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving epidemic // Clin. Infect. Dis. 2012. N 55. P. 1408-1416.
References:
1. Bakulin I. G., Kiseleva A. V. Prakticheskie aspekty primeneniya trekhkomponentnoi terapii pri khronicheskom gepatite S [Triple therapy for chronic hepatitis C: Practical Aspects]. Terapevticheskii arkhiv [Therapeutic Archives]. 2013, 11, pp. 91-100. [in Russian]
2. Batskikh S. N., Morozov S. V., Chulanov V. P., Pokrovskii V. I. Virus gepatita S 3-go genotipa: takoi “prostoi”, takoi “slozhnyi” [Hepatitis C virus genotype 3 rd: a “simpl”e, a “complex”]. Terapevticheskii arkhiv [Therapeutic Archives]. 2012, 11, p. 4. [in Russian]
3. Bueverov A. O. Profilaktika i korrektsiya gematologicheskikh pobochnykh effektov protivovirusnoi terapii khronicheskogo gepatita S [Prevention and correction of hematological side effects of antiviral therapy for chronic hepatitis C]. Ros. zhurn. gastroenterol., gepatol., koloproktol. [Russian J. of Gastroenterology, Hepatology, Coloproctology]. 2009, 3, pp. 76-82. [in Russian]
4. VICh-infektsiya i SPID: natsional'noe rukovodstvo [HIV and AIDS: national leadership] (V. V. Pokrovskii). Moscow, GJeOTAR-Media, 2013, 608 p.
5. Gromova I. I., Bogomolov B. P. Sravnitel'naya effektivnost' i pobochnye reaktsii pri kombinirovannoi protivovirusnoi terapii bol'nykh khronicheskim gepatitom S [Comparative effectiveness and side effects of combined antiviral therapy in patients with chronic hepatitis C]. Klinicheskaya meditsina [Clinical medicine]. 2008, 9, pp. 43-46. [in Russian]
6. Doskozhaeva S. T., Petrova N. P. Terapiya khronicheskogo virusnogo gepatita S u bol'nykh VICh-infektsiei [The therapy of chronical hepatitis (type C) of patients who have HIV-infection]. Meditsina [Medicine]. 2008, 8, pp. 10-13.
7. Ivashkin V. T., Maevskaya M. V., Morozova M. A., Lyusina E. O. Sovremennye skhemy lecheniya bol'nykh khronicheskim gepatitom S [Current treatment regimens for patients with chronic hepatitis C]. Ros. zhurn. gastroenterol., gepatol., koloproktol. [Russian J. of Gastroenterology, Hepatology, Coloproctology]. 2012, 1, pp. 36-45. [in Russian]
8. Infektsionnye bolezni: natsional'noe rukovodstvo [Infectious diseases: national leadership] (N. D. Yushchuk, Yu. Ya. Vengerov). Moscow, GEOTAR-Media, 2009, 1056 p.
9. Kasymova T. V. Pobochnye deistviya protivovirusnogo lecheniya khronicheskogo virusnogo gepatita S [Side effects of antiviral treatment of chronic hepatitis C]. Vestnik YuKGFA [Bulletin YUKGFA]. 2012, 3, pp. 128-130.
10. Maksimov S. L., Ivanova L. M., Kravchenko A. V., Serebrovskaya L. V., Ol'shanskii A. Ya., Morgunova N. M., Yushchuk N. D. Osobennosti terapii khronicheskogo gepatita S pegilirovannym interferonom α2a i ribavirinom u bol'nykh VICh-infektsiei [Chronic hepatitis C treatment with pegilated interferon alpha2a and ribavirin in patients with HIV-infection]. Terapevticheskii arkhiv [Therapeutic Archives]. 2007, 11, p. 40. [in Russian]
11. Minaeva S. V., Moshkovich G. F., Goryaeva M. P., Voronina I. D. Sravnitel'nye rezul'taty lecheniya khronicheskogo gepatita S u bol'nykh VICh-infektsiei, poluchayushchikh i ne poluchayushchikh antiretrovirusnuyu terapiyu [Comparative results of treatment for chronic hepatitis C in HIVinfected patients receiving and not receiving highly active antiretroviral therapy]. Epidemiologiya i infektsionnye bolezni [Epidemiology and Infectious Diseases]. 2010, 3, pp. 35-38. [in Russian]
12. Rezolyutsiya pervoi Evropeiskoi soglasitel'noi konferentsii po lecheniyu khronicheskikh gepatitov V i S u VICh-infitsirovannykh [Resolution of the first European Consensus conference on the treatment of chronic hepatitis B and C in HIV-infected]. Standarty meditsiny [Standards medicine]. 2006, 1, pp. 39-48.
13. Sarkisyants N. K., Grigoryan E. G. Opyt prognozirovaniya pobochnykh effektov lecheniya khronicheskogo gepatita S peginterferonom α-2A s ribavirinom [Experience predict the side effects of treatment of chronic hepatitis C with peginterferon α-2A with ribavirin]. Klinicheskaya meditsina [Clinical medicine]. 2013, 5, pp. 46-49. [in Russian]
14. Sklyar L. F., Gorelova I. S., Li Yu. A. Protivovirusnaya terapiya parenteral'nykh gepatitov u VICh-infitsirovannykh patsientov v Primorskom krae [Antiviral therapy parenteral hepatitis in HIV-infected patients in the Primorye Territory]. Tikhookeanskii meditsinskii zhurnal [Pacific Medical Journal]. 2009, 4, pp. 80-82. [in Russian]
15. Fedorchenko S. V., Martynovich T. L., Lyashko O. V., Karyuk Zh. A., Yanchenko V. I. Spontannyi klirens HCV: svyaz' s polom, vozrastom, genotipom virusa, putyami peredachi infektsii, markerami HBV i HIV [Spontaneous clearance of HCV: relationship with sex, age, genotype, routes of infection, markers of HBV and HIV]. Terapevticheskii arkhiv [Therapeutic Archives]. 2010, 3, p. 52. [in Russian]
16. Shakhgil'dyan V. I. Sovremennye podkhody k lecheniyu HCV-infektsii u VICh-infitsirovannykh [Modern approaches to the therapy of chronic hepatitis C of patients who have HIV-infection]. Gepatol. forum. [Gepatol. forum.]. 2008, 4, pp.16-27.
17. Yushchuk N. D., Maksimov S. L., Ivanova L. M., Klimova E. A., Znoiko O. O., Kravchenko A. V. Kombinirovannaya terapiya khronicheskogo gepatita S pegilirovannym interferonom α-2a i ribavirinom u bol'nykh s VICh-infektsiei i bol'nykh s monoinfektsiei HCV [Combined treatment of chronic hepatitis C by pegilated interferon-2a and ribavirin in patients with HIV-infection and patients with HCV monoinfection]. Ros. zhurn. gastroenterol., gepatol., koloproktol. [Russian J. of Gastroenterology, Hepatology, Coloproctology]. 2009, 1, pp. 35-43. [in Russian]
18. Andreoni M. et al. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci. 2012, 16(11), pp. 1473-1483.
19. Ascione A. et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomized trial. 43-rd Annual meeting of the European association for the study of the liver (EASL). Apr. 23-27, 2008, Milan, Italy, 2008.
20. Balagopal A. et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 2008, 135, pp. 226-233.
21. Barreiro P. et al. Comparison of hepatitis C virus early kinetics in HIV/HCV-co-infected patients treated with weight-based ribavirin + either pegIFN alpha-2a or pegIFN alpha-2b. 14th Conference on retroviruses and opportunistic infections (CROI). Los Angeles, Febr. 25-28, 2007, Abstract 901.
22. Berenguer J. et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol. 2013, 58(6), pp. 1104-1112.
23. Bichoupan K. et al. Pegylated-IFN α2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new. Expert Opin Biol Ther. 2014, 14(9), pp. 1369-1378.
24. Chapplain J. et al. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial. J Infect. 2013, 67(4), pp. 313-321.
25. Garbuglia A. et al. HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes. Infect Dis. 2014, 14, p. 222.
26. Gonzales-Garcia J. et al. The use of TDF + 3TC/FTC is associated with an improved response to pegylated interferon + ribavirin in HIV/HCV-co-infected patients receiving HAART: The Gesida 50/06 Study Group. 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, MA. Feb. 3-6, 2008, Abstract 1076.
27. Hepatitis C and HIV-infection: management algorithm in patients with combined infection. WHO Clinical protocol for European region. 2009. Available at: http://www.euro.who.int/_data/assets/pdf_file/0010/78148/HEP_C_rus.pdf (accessed 03.11.2014).
28. Jain M. et al. Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients. J Viral Hepat. 2015, 22(1), pp. 25-36.
29. Khaykin P. et al. Impact of different ART regimens on efficacy and safety of standard HCV treatment in HIV/HCV co-infected patients. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract MOREB056.
30. Krämer B. et al. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C. AIDS. 2013, 27(17), pp. 2817-2819.
31. Labarga P. et al. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. J Viral Hepat. 2014, 21(7), pp. 475-479.
32. Limketkai B. et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012, 308, pp. 370-378.
33. Lu L. et al. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol. 2005, 75, pp. 538-549.
34. Maida I. et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes. AIDS. 2006, 22, pp. 139-143.
35. Mallolas J. et al. Peginterferon Alfa-2b plus ribavirin for treatment naïve patients coinfected with HCV and HIV. Expert. Rev. Antiinfect. Ther. 2008, 6, pp. 281-289.
36. Mandorfer M. et al. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Liver Int. 2014, 34(1), pp. 69-77.
37. Marks K. et al. Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. J Acquir Immune Defic Syndr. 2014, 65(3), pp. 345-349.
38. Mira J. et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013, 56(11), pp. 1646-1653.
39. Mira J. et al. Efficacy of pegylated interferon + ribavirin treatment in HIV/HCV-co-infected patients receiving abacavir + lamivudine or tenofovir + either lamivudine or emtricitabine as nucleoside analogue backbone. 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, MA. Feb. 3-6, 2008, Abstract 1074.
40. Murphy D. et al. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′untranslated region sequences. Journal of Clinical Microbiology. 2007, 45, pp. 1102-1112.
41. Nunez M. et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res. Hum. Retroviruses. 2007, 23, pp. 972-982.
42. Nunez M. et al. Extended treatment does not reduce relapses in HIV/HCV-co-infected patients treated with pegylated interferon + weight-dosing ribavirin. In: 14th Conference on retroviruses and opportunistic infections (CROI). Los. Angeles, Febr. 25-28, 2007, Abstract 899.
43. Odolini S. et al. Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV. Infect Dis. 2014, 14(5).
44. Osinusi A. et al. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients. J Med Virol. 2014, 86(2), pp. 177-185.
45. Rivero-Juárez A. et al. Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients. PLoS One. 2012, 7(11).
46. Rivero-Juarez A. et al. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. AIDS. 2013, 27(12), pp. 1941-1947.
47. Rivero-Juarez A. et al. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. J Infect. 2014, 68(4), pp. 372-377.
48. Rockstroh J. et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008, 9, pp. 82-88.
49. Salmon-Ceron D. et al. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1. Liver Int. 2014, 34(6), pp. 869-889.
50. Sede M. et al. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin. Arch Virol. 2013, 158(9), pp. 1907-1915.
51. Serrano-Villar S. et al. Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections. Clin Infect Dis. 2013, 57(3), pp. 458-464.
52. Simmonds P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005, 42, pp. 962-973.
53. Slim J. et al. The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV. J Int Assoc Provid AIDS Care. 2013, 12(5), pp. 354-362.
54. Sogni P. et al. Management of cirrhosis complications in HIV patients coinfected with hepatitis В or С virus. La Presse Medicaid. 2005, 20(34), pp. 1579-1583.
55. Soriano V. et al. Management of chronic hepatitis B and C in HIV-coinfected patients. J. Antimicrob. Chemother. 2006, 57, pp. 815-818.
56. Soriano V. et al. (PRESCO Study Group). Causes of premature discontinuation in HIV/HCV co-infected patients in PRESCO, a large trial of treatment with pegylated interferon plus weight-based ribavirin. In: 14th Conference on retroviruses and opportunistic infections (CROI). Los. Angeles, Febr. 25-28, 2007, Abstract 905.
57. Soriano V. et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007, 21, pp. 1073-1089.
58. Strazzulla A. et al. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals. Infect Dis. 2014, 14(5).
59. Sulkowski M. HCV therapy in HIV-infected patients. Liver Int. 2013, 33(1), pp. 63-67.
60. Sulkowski M. Management of acute and chronic HCV infection in persons with HIV coinfection. Hepatology. 2014, 61, pp. 108-119.
61. Sulkowski M. Viral hepatitis and HIV coinfection. Hepatology. 2008, 48, pp. 353-367.
62. Tian D. et al. Different HCV genotype distributions of HIV-infected individuals in Henan and Guangxi, China. PLoS One. 2012, 7(11).
63. Torti C. et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. AIDS. 2006, 41, pp. 180-185.
64. Vachon M.-L. et al. HCV treatment challenges in patients co-infected with HIV. Future HIV Ther. 2009, 1, pp. 87-100.
65. Wandeler G. et al. Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving epidemic. Clin. Infect. Dis. 2012, 55, pp. 1408-1416.
1. Бакулин И. Г., Киселева А. В. Практические аспекты применения трехкомпонентной терапии при хроническом гепатите С // Терапевтический архив. 2013. № 11. С. 91-100.
2. Бацких С. Н., Морозов С. В., Чуланов В. П., Покровский В. И. Вирус гепатита С 3-го генотипа: такой «простой», такой «сложный» // Терапевтический архив. 2012. № 11. С. 4.
3. Буеверов А. О. Профилактика и коррекция гематологических побочных эффек-тов противовирусной терапии хронического гепатита С // Рос. журн. гастроэнтерол., гепатол., колопроктол. 2009. № 3. С. 76-82.
4. ВИЧ-инфекция и СПИД: национальное руководство / Под ред. В. В. Покровского. М.: ГЭОТАР-Медиа, 2013. 608 с.
5. Громова И. И., Богомолов Б. П. Сравнительная эффективность и побочные реакции при комбинированной противо-вирусной терапии больных хроническим гепатитом С // Клиническая медицина. 2008. № 9. С. 43-46.
6. Доскожаева С. Т., Петрова Н. П. Терапия хронического вирусного гепатита С у больных ВИЧ-инфекцией // Медицина. 2008. № 8. С. 10-13.
7. Ивашкин В. Т., Маевская М. В., Морозова М. А., Люсина Е. О. Современные схемы лечения больных хроническим гепатитом С // Рос. журн. гастроэнтерол., гепатол., колопроктол. 2012. № 1. С. 36-45.
8. Инфекционные болезни: национальное руководство / Под ред. Н. Д. Ющука, Ю. Я. Венгерова. M.: GEOTAR-Media, 2009. 1056 c.
9. Касымова Т. В. Побочные действия противовирусного лечения хронического вирусного гепатита С // Вестник ЮКГФА. 2012. № 3. С. 128-130.
10. Максимов С. Л., Иванова Л. М., Кравченко А. В., Серебровская Л. В., Ольшанский А. Я., Моргунова Н. М., Ющук Н. Д. Особенности терапии хронического гепатита С пегилированным интерфероном α2а и рибавирином у больных ВИЧ-инфекцией // Терапевтический архив. 2007. № 11. С. 40.
11. Минаева С. В., Мошкович Г. Ф., Горяева М. П., Воронина И. Д. Сравнительные результаты лечения хронического гепатита С у больных ВИЧ-инфекцией, получающих и не получающих антиретровирусную терапию // Эпидемиология и инфекционные болезни. 2010. № 3. С. 35-38.
12. Резолюция первой Европейской согласительной конференции по лечению хронических гепатитов В и С у ВИЧ-инфицированных. Стандарты медицины. 2006. № 1. С. 39-48.
13. Саркисянц Н. К., Григорян Э. Г. Опыт прогнозирования побочных эффектов лечения хронического гепатита С пегинтерфероном α-2А с рибавирином // Клиническая медицина. 2013. № 5. С. 46-49.
14. Скляр Л. Ф., Горелова И. С., Ли Ю. А. Противовирусная терапия парентеральных гепатитов у ВИЧ-инфицированных пациентов в Приморском крае // Тихоокеанский медицинский журнал. 2009. № 4. С. 80-82.
15. Федорченко С. В., Мартынович Т. Л., Ляшко О. В., Карюк Ж. А., Янченко В. И. Спонтанный клиренс HCV: связь с полом, возрастом, генотипом вируса, путями передачи инфекции, маркерами HBV и HIV // Терапевтический архив. 2010. № 3. С. 52.
16. Шахгильдян В. И. Современные подходы к лечению HCV-инфекции у ВИЧ-инфицированных. Гепатол. форум. 2008. № 4. С.16-27.
17. Ющук Н. Д., Максимов С. Л., Иванова Л. М., Климова Е. А., Знойко О. О., Кравченко А. В. Комбинированная терапия хронического гепатита С пегилированным интерфероном α-2а и рибавирином у больных с ВИЧ-инфекцией и больных с моноинфекцией HCV // Рос. журн. гастроэнтерол., гепатол., колопроктол. 2009. № 1. С. 35-43.
18. Andreoni M. et al. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications // Eur Rev Med Pharmacol Sci. 2012. N 16(11). P. 1473-1483.
19. Ascione A. et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomized trial // 43-rd Annual meeting of the European association for the study of the liver (EASL). Apr. 23-27, 2008; Milan, Italy; 2008.
20. Balagopal A. et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C // Gastroenterology. 2008. N 135. P. 226-233.
21. Barreiro P. et al. Comparison of hepatitis C virus early kinetics in HIV/HCV-co-infected patients treated with weight-based ribavirin + either pegIFN alpha-2a or pegIFN alpha-2b // 14th Conference on retroviruses and opportunistic infections (CROI). Los Angeles, Febr. 25-28, 2007. Abstract 901.
22. Berenguer J. et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus // J Hepatol. 2013. N 58(6). P. 1104-1112.
23. Bichoupan K. et al. Pegylated-IFN α2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new // Expert Opin Biol Ther. 2014. N 14(9). P. 1369-1378.
24. Chapplain J. et al. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial // J Infect. 2013. N 67(4). P. 313-321.
25. Garbuglia A. et al. HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes // Infect Dis. 2014. N 14. P. 222.
26. Gonzales-Garcia J. et al. The use of TDF + 3TC/FTC is associated with an improved response to pegylated interferon + ribavirin in HIV/HCV-co-infected patients receiving HAART: The Gesida 50/06 Study Group // 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, MA. Feb. 3-6, 2008. Abstract 1076.
27. Hepatitis C and HIV-infection: management algorithm in patients with combined infection. WHO Clinical protocol for European region. 2009. URL: http://www.euro.who.int/_data/assets/pdf_file/0010/78148/HEP_C_rus.pdf (дата обращения 03.11.2014).
28. Jain M. et al. Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients // J Viral Hepat. 2015. N 22(1). P. 25-36.
29. Khaykin P. et al. Impact of different ART regimens on efficacy and safety of standard HCV treatment in HIV/HCV co-infected patients // 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract MOREB056.
30. Krämer B. et al. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C // AIDS. 2013. N 27(17). P. 2817-2819.
31. Labarga P. et al. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy // J Viral Hepat. 2014. N 21(7). P. 475-479.
32. Limketkai B. et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV // JAMA. 2012. N 308. P. 370-378.
33. Lu L. et al. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants // J Med Virol. 2005. N 75. P. 538-549.
34. Maida I. et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes // AIDS. 2006. N 22. P. 139-143.
35. Mallolas J. et al. Peginterferon Alfa-2b plus ribavirin for treatment naïve patients coinfected with HCV and HIV // Expert. Rev. Antiinfect. Ther. 2008. N 6. P. 281-289.
36. Mandorfer M. et al. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin // Liver Int. 2014. N 34(1). P. 69-77.
37. Marks K. et al. Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239 // J Acquir Immune Defic Syndr. 2014. N 65(3). P. 345-349.
38. Mira J. et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis // Clin Infect Dis. 2013. N 56(11). P. 1646-1653.
39. Mira J. et al. Efficacy of pegylated interferon + ribavirin treatment in HIV/HCV-co-infected patients receiving abacavir + lamivudine or tenofovir + either lamivudine or emtricitabine as nucleoside analogue backbone // 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, MA. Feb. 3-6, 2008. Abstract 1074.
40. Murphy D. et al. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′untranslated region sequences // Journal of Clinical Microbiology. 2007. N 45. P. 1102-1112.
41. Nunez M. et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial // AIDS Res. Hum. Retroviruses. 2007. N 23. P. 972-982.
42. Nunez M. et al. Extended treatment does not reduce relapses in HIV/HCV-co-infected patients treated with pegylated interferon + weight-dosing ribavirin. In: 14th Conference on retroviruses and opportunistic infections (CROI). Los. Angeles, Febr. 25-28, 2007. Abstract 899.
43. Odolini S. et al. Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV // Infect Dis. 2014. N 14(5).
44. Osinusi A. et al. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients // J Med Virol. 2014. 86(2). P. 177-185.
45. Rivero-Juárez A. et al. Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients // PLoS One. 2012. N 7(11).
46. Rivero-Juarez A. et al. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype // AIDS. 2013. 27(12). P. 1941-1947.
47. Rivero-Juarez A. et al. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy // J Infect. 2014. N 68(4). P. 372-377.
48. Rockstroh J. et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults // HIV Med. 2008. N 9. P. 82-88.
49. Salmon-Ceron D. et al. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1 // Liver Int. 2014. N 34(6). P. 869-889.
50. Sede M. et al. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin // Arch Virol. 2013. 158(9). P. 1907-1915.
51. Serrano-Villar S. et al. Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections // Clin Infect Dis. 2013. N 57(3). P. 458-464.
52. Simmonds P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes // Hepatology. 2005. N 42. P. 962-973.
53. Slim J. et al. The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV // J Int Assoc Provid AIDS Care. 2013. N 12(5). P. 354-362.
54. Sogni P. et al. Management of cirrhosis complications in HIV patients coinfected with hepatitis В or С virus // La Presse Medicaid. 2005. N 20(34). P. 1579-1583.
55. Soriano V. et al. Management of chronic hepatitis B and C in HIV-coinfected patients // J. Antimicrob. Chemother. 2006. N 57. P. 815-818.
56. Soriano V. et al. (PRESCO Study Group). Causes of premature discontinuation in HIV/HCV co-infected patients in PRESCO, a large trial of treatment with pegylated interferon plus weight-based ribavirin. In: 14th Conference on retroviruses and opportunistic infections (CROI). Los. Angeles, Febr. 25-28, 2007. Abstract 905.
57. Soriano V. et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel // AIDS. 2007. N 21. P. 1073-1089.
58. Strazzulla A. et al. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals // Infect Dis. 2014. N 14(5).
59. Sulkowski M. HCV therapy in HIV-infected patients // Liver Int. 2013. 33(1). P. 63-67.
60. Sulkowski M. Management of acute and chronic HCV infection in persons with HIV coinfection // Hepatology. 2014. N 61. P. 108-119.
61. Sulkowski M. Viral hepatitis and HIV coinfection // Hepatology. 2008. N 48. P. 353-367.
62. Tian D. et al. Different HCV genotype distributions of HIV-infected individuals in Henan and Guangxi, China. PLoS One. 2012. N 7(11).
63. Torti C. et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort // AIDS. 2006. N 41. P. 180-185.
64. Vachon M. L. et al. HCV treatment challenges in patients co-infected with HIV // Future HIV Ther. 2009. N 1. P. 87-100.
65. Wandeler G. et al. Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving epidemic // Clin. Infect. Dis. 2012. N 55. P. 1408-1416.
References:
1. Bakulin I. G., Kiseleva A. V. Prakticheskie aspekty primeneniya trekhkomponentnoi terapii pri khronicheskom gepatite S [Triple therapy for chronic hepatitis C: Practical Aspects]. Terapevticheskii arkhiv [Therapeutic Archives]. 2013, 11, pp. 91-100. [in Russian]
2. Batskikh S. N., Morozov S. V., Chulanov V. P., Pokrovskii V. I. Virus gepatita S 3-go genotipa: takoi “prostoi”, takoi “slozhnyi” [Hepatitis C virus genotype 3 rd: a “simpl”e, a “complex”]. Terapevticheskii arkhiv [Therapeutic Archives]. 2012, 11, p. 4. [in Russian]
3. Bueverov A. O. Profilaktika i korrektsiya gematologicheskikh pobochnykh effektov protivovirusnoi terapii khronicheskogo gepatita S [Prevention and correction of hematological side effects of antiviral therapy for chronic hepatitis C]. Ros. zhurn. gastroenterol., gepatol., koloproktol. [Russian J. of Gastroenterology, Hepatology, Coloproctology]. 2009, 3, pp. 76-82. [in Russian]
4. VICh-infektsiya i SPID: natsional'noe rukovodstvo [HIV and AIDS: national leadership] (V. V. Pokrovskii). Moscow, GJeOTAR-Media, 2013, 608 p.
5. Gromova I. I., Bogomolov B. P. Sravnitel'naya effektivnost' i pobochnye reaktsii pri kombinirovannoi protivovirusnoi terapii bol'nykh khronicheskim gepatitom S [Comparative effectiveness and side effects of combined antiviral therapy in patients with chronic hepatitis C]. Klinicheskaya meditsina [Clinical medicine]. 2008, 9, pp. 43-46. [in Russian]
6. Doskozhaeva S. T., Petrova N. P. Terapiya khronicheskogo virusnogo gepatita S u bol'nykh VICh-infektsiei [The therapy of chronical hepatitis (type C) of patients who have HIV-infection]. Meditsina [Medicine]. 2008, 8, pp. 10-13.
7. Ivashkin V. T., Maevskaya M. V., Morozova M. A., Lyusina E. O. Sovremennye skhemy lecheniya bol'nykh khronicheskim gepatitom S [Current treatment regimens for patients with chronic hepatitis C]. Ros. zhurn. gastroenterol., gepatol., koloproktol. [Russian J. of Gastroenterology, Hepatology, Coloproctology]. 2012, 1, pp. 36-45. [in Russian]
8. Infektsionnye bolezni: natsional'noe rukovodstvo [Infectious diseases: national leadership] (N. D. Yushchuk, Yu. Ya. Vengerov). Moscow, GEOTAR-Media, 2009, 1056 p.
9. Kasymova T. V. Pobochnye deistviya protivovirusnogo lecheniya khronicheskogo virusnogo gepatita S [Side effects of antiviral treatment of chronic hepatitis C]. Vestnik YuKGFA [Bulletin YUKGFA]. 2012, 3, pp. 128-130.
10. Maksimov S. L., Ivanova L. M., Kravchenko A. V., Serebrovskaya L. V., Ol'shanskii A. Ya., Morgunova N. M., Yushchuk N. D. Osobennosti terapii khronicheskogo gepatita S pegilirovannym interferonom α2a i ribavirinom u bol'nykh VICh-infektsiei [Chronic hepatitis C treatment with pegilated interferon alpha2a and ribavirin in patients with HIV-infection]. Terapevticheskii arkhiv [Therapeutic Archives]. 2007, 11, p. 40. [in Russian]
11. Minaeva S. V., Moshkovich G. F., Goryaeva M. P., Voronina I. D. Sravnitel'nye rezul'taty lecheniya khronicheskogo gepatita S u bol'nykh VICh-infektsiei, poluchayushchikh i ne poluchayushchikh antiretrovirusnuyu terapiyu [Comparative results of treatment for chronic hepatitis C in HIVinfected patients receiving and not receiving highly active antiretroviral therapy]. Epidemiologiya i infektsionnye bolezni [Epidemiology and Infectious Diseases]. 2010, 3, pp. 35-38. [in Russian]
12. Rezolyutsiya pervoi Evropeiskoi soglasitel'noi konferentsii po lecheniyu khronicheskikh gepatitov V i S u VICh-infitsirovannykh [Resolution of the first European Consensus conference on the treatment of chronic hepatitis B and C in HIV-infected]. Standarty meditsiny [Standards medicine]. 2006, 1, pp. 39-48.
13. Sarkisyants N. K., Grigoryan E. G. Opyt prognozirovaniya pobochnykh effektov lecheniya khronicheskogo gepatita S peginterferonom α-2A s ribavirinom [Experience predict the side effects of treatment of chronic hepatitis C with peginterferon α-2A with ribavirin]. Klinicheskaya meditsina [Clinical medicine]. 2013, 5, pp. 46-49. [in Russian]
14. Sklyar L. F., Gorelova I. S., Li Yu. A. Protivovirusnaya terapiya parenteral'nykh gepatitov u VICh-infitsirovannykh patsientov v Primorskom krae [Antiviral therapy parenteral hepatitis in HIV-infected patients in the Primorye Territory]. Tikhookeanskii meditsinskii zhurnal [Pacific Medical Journal]. 2009, 4, pp. 80-82. [in Russian]
15. Fedorchenko S. V., Martynovich T. L., Lyashko O. V., Karyuk Zh. A., Yanchenko V. I. Spontannyi klirens HCV: svyaz' s polom, vozrastom, genotipom virusa, putyami peredachi infektsii, markerami HBV i HIV [Spontaneous clearance of HCV: relationship with sex, age, genotype, routes of infection, markers of HBV and HIV]. Terapevticheskii arkhiv [Therapeutic Archives]. 2010, 3, p. 52. [in Russian]
16. Shakhgil'dyan V. I. Sovremennye podkhody k lecheniyu HCV-infektsii u VICh-infitsirovannykh [Modern approaches to the therapy of chronic hepatitis C of patients who have HIV-infection]. Gepatol. forum. [Gepatol. forum.]. 2008, 4, pp.16-27.
17. Yushchuk N. D., Maksimov S. L., Ivanova L. M., Klimova E. A., Znoiko O. O., Kravchenko A. V. Kombinirovannaya terapiya khronicheskogo gepatita S pegilirovannym interferonom α-2a i ribavirinom u bol'nykh s VICh-infektsiei i bol'nykh s monoinfektsiei HCV [Combined treatment of chronic hepatitis C by pegilated interferon-2a and ribavirin in patients with HIV-infection and patients with HCV monoinfection]. Ros. zhurn. gastroenterol., gepatol., koloproktol. [Russian J. of Gastroenterology, Hepatology, Coloproctology]. 2009, 1, pp. 35-43. [in Russian]
18. Andreoni M. et al. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci. 2012, 16(11), pp. 1473-1483.
19. Ascione A. et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomized trial. 43-rd Annual meeting of the European association for the study of the liver (EASL). Apr. 23-27, 2008, Milan, Italy, 2008.
20. Balagopal A. et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 2008, 135, pp. 226-233.
21. Barreiro P. et al. Comparison of hepatitis C virus early kinetics in HIV/HCV-co-infected patients treated with weight-based ribavirin + either pegIFN alpha-2a or pegIFN alpha-2b. 14th Conference on retroviruses and opportunistic infections (CROI). Los Angeles, Febr. 25-28, 2007, Abstract 901.
22. Berenguer J. et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol. 2013, 58(6), pp. 1104-1112.
23. Bichoupan K. et al. Pegylated-IFN α2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new. Expert Opin Biol Ther. 2014, 14(9), pp. 1369-1378.
24. Chapplain J. et al. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial. J Infect. 2013, 67(4), pp. 313-321.
25. Garbuglia A. et al. HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes. Infect Dis. 2014, 14, p. 222.
26. Gonzales-Garcia J. et al. The use of TDF + 3TC/FTC is associated with an improved response to pegylated interferon + ribavirin in HIV/HCV-co-infected patients receiving HAART: The Gesida 50/06 Study Group. 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, MA. Feb. 3-6, 2008, Abstract 1076.
27. Hepatitis C and HIV-infection: management algorithm in patients with combined infection. WHO Clinical protocol for European region. 2009. Available at: http://www.euro.who.int/_data/assets/pdf_file/0010/78148/HEP_C_rus.pdf (accessed 03.11.2014).
28. Jain M. et al. Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients. J Viral Hepat. 2015, 22(1), pp. 25-36.
29. Khaykin P. et al. Impact of different ART regimens on efficacy and safety of standard HCV treatment in HIV/HCV co-infected patients. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract MOREB056.
30. Krämer B. et al. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C. AIDS. 2013, 27(17), pp. 2817-2819.
31. Labarga P. et al. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. J Viral Hepat. 2014, 21(7), pp. 475-479.
32. Limketkai B. et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012, 308, pp. 370-378.
33. Lu L. et al. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol. 2005, 75, pp. 538-549.
34. Maida I. et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes. AIDS. 2006, 22, pp. 139-143.
35. Mallolas J. et al. Peginterferon Alfa-2b plus ribavirin for treatment naïve patients coinfected with HCV and HIV. Expert. Rev. Antiinfect. Ther. 2008, 6, pp. 281-289.
36. Mandorfer M. et al. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Liver Int. 2014, 34(1), pp. 69-77.
37. Marks K. et al. Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. J Acquir Immune Defic Syndr. 2014, 65(3), pp. 345-349.
38. Mira J. et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013, 56(11), pp. 1646-1653.
39. Mira J. et al. Efficacy of pegylated interferon + ribavirin treatment in HIV/HCV-co-infected patients receiving abacavir + lamivudine or tenofovir + either lamivudine or emtricitabine as nucleoside analogue backbone. 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, MA. Feb. 3-6, 2008, Abstract 1074.
40. Murphy D. et al. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′untranslated region sequences. Journal of Clinical Microbiology. 2007, 45, pp. 1102-1112.
41. Nunez M. et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res. Hum. Retroviruses. 2007, 23, pp. 972-982.
42. Nunez M. et al. Extended treatment does not reduce relapses in HIV/HCV-co-infected patients treated with pegylated interferon + weight-dosing ribavirin. In: 14th Conference on retroviruses and opportunistic infections (CROI). Los. Angeles, Febr. 25-28, 2007, Abstract 899.
43. Odolini S. et al. Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV. Infect Dis. 2014, 14(5).
44. Osinusi A. et al. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients. J Med Virol. 2014, 86(2), pp. 177-185.
45. Rivero-Juárez A. et al. Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients. PLoS One. 2012, 7(11).
46. Rivero-Juarez A. et al. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. AIDS. 2013, 27(12), pp. 1941-1947.
47. Rivero-Juarez A. et al. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. J Infect. 2014, 68(4), pp. 372-377.
48. Rockstroh J. et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008, 9, pp. 82-88.
49. Salmon-Ceron D. et al. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1. Liver Int. 2014, 34(6), pp. 869-889.
50. Sede M. et al. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin. Arch Virol. 2013, 158(9), pp. 1907-1915.
51. Serrano-Villar S. et al. Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections. Clin Infect Dis. 2013, 57(3), pp. 458-464.
52. Simmonds P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005, 42, pp. 962-973.
53. Slim J. et al. The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV. J Int Assoc Provid AIDS Care. 2013, 12(5), pp. 354-362.
54. Sogni P. et al. Management of cirrhosis complications in HIV patients coinfected with hepatitis В or С virus. La Presse Medicaid. 2005, 20(34), pp. 1579-1583.
55. Soriano V. et al. Management of chronic hepatitis B and C in HIV-coinfected patients. J. Antimicrob. Chemother. 2006, 57, pp. 815-818.
56. Soriano V. et al. (PRESCO Study Group). Causes of premature discontinuation in HIV/HCV co-infected patients in PRESCO, a large trial of treatment with pegylated interferon plus weight-based ribavirin. In: 14th Conference on retroviruses and opportunistic infections (CROI). Los. Angeles, Febr. 25-28, 2007, Abstract 905.
57. Soriano V. et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007, 21, pp. 1073-1089.
58. Strazzulla A. et al. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals. Infect Dis. 2014, 14(5).
59. Sulkowski M. HCV therapy in HIV-infected patients. Liver Int. 2013, 33(1), pp. 63-67.
60. Sulkowski M. Management of acute and chronic HCV infection in persons with HIV coinfection. Hepatology. 2014, 61, pp. 108-119.
61. Sulkowski M. Viral hepatitis and HIV coinfection. Hepatology. 2008, 48, pp. 353-367.
62. Tian D. et al. Different HCV genotype distributions of HIV-infected individuals in Henan and Guangxi, China. PLoS One. 2012, 7(11).
63. Torti C. et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. AIDS. 2006, 41, pp. 180-185.
64. Vachon M.-L. et al. HCV treatment challenges in patients co-infected with HIV. Future HIV Ther. 2009, 1, pp. 87-100.
65. Wandeler G. et al. Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving epidemic. Clin. Infect. Dis. 2012, 55, pp. 1408-1416.
Көрген адамдардың саны: 544
Мақалалар санаты:
Әдебиеттерге шолу
Библиографиялық сілтемелер
Сәрсекеева Н. Е., Кошерова Б. Н. АИВ-инфекцияланған науқастардағы созылмалы С гепатитінің емдеу ерекшеліктері: әдебиеттерді шолу / / Ғылым және Денсаулық сақтау. 2015. № 4. Б. 18-28.
Ұқсас жариялымдар:
ІШ АСУЫНЫҢ ЗАРАҚАТЫНДАҒЫ ДИАГНОСТИКАЛЫҚ ЖӘНЕ ЕМДЕУ ЛАПАРОСКОПИЯСЫ. ӘДЕБИЕТТЕРДІ ШОЛУ.
БІРІНШІЛІК БИЛИАРЛЫ ХОЛАНГИТІ БАР НАУҚАСТАРДЫҢ ӨМІР САПАСЫ МЕН ОНЫ БАҒАЛАУДЫҢ ӘДІСТЕРІ
БАУЫРДЫҢ ДӘРІЛІК-ИНДУКЦИЯЛАНҒАН ЗАҚЫМДАНУЫ ЖӘНЕ ГЕНДЕРЛІК АЙЫРМАШЫЛЫҚТАР
КӨП АҒЗАЛЫ ДИСФУНКЦИЯСЫ БАР НАУҚАСТАРДАҒЫ ИНТРААБДОМИНАЛЬДЫ ГИПЕРТЕНЗИЯ МЕН АСҚАЗАН-ІШЕК ЖОЛДАРЫНЫҢ ЗАҚЫМДАНУ МАРКЕРЛЕРІНІҢ ӨЗАРА БАЙЛАНЫСЫ
ЖЕДЕЛ КОРОНАРЛЫҚ СИНДРОМ МЕН КӨМІРСУЛАР АЛМАСУЫНЫҢ БҰЗЫЛУЫНЫҢ БАЙЛАНЫСЫ